CLRB
Cellectar Biosciences, Inc.
$2.59
-5.82%
$20.7M
No data for this timeframe.
Vol
Market Cap$20.7M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders3 funds
Inst. Value$264.5K
Inst. Activity2 buys / 1 sells
Insider Activity4B / 0S
Insider Net $$50.5K
SEC Reports10
Press Releases4
Recent Activity
Jun 5, 2026
SEC
Cellectar Biosciences filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting sched
DEFA14A — Impact 4/10
Jun 1, 2026
fda
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
<p align="center"><em>Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Mo
May 29, 2026
SEC
Cellectar Biosciences filed Amendment No. 1 to its S-1 registration statement to register up to 51,998,413 shares of com
S-1/A — Impact 6/10
May 19, 2026
SEC
Cellectar Biosciences filed an S-1 registration statement to register up to 51.2 million shares of common stock for resa
S-1 — Impact 6/10
May 7, 2026
Insider
CARUSO JAMES V bought 8,680 shares
Chief Executive Officer @ $2.88 ($25.0K)
May 7, 2026
Insider
CARUSO JAMES V bought 26,040 shares
Chief Executive Officer @ $0.0100 ($260.40)
May 7, 2026
Insider
Longcor Jarrod bought 8,680 shares
Chief Operating Officer @ $2.88 ($25.0K)
Inst.
VANGUARD GROUP INC — ADD
89,120 shares ($262.9K)
Price Targets
$10.33
+299.0% upside
Strong Buy
Current $2.59
Low $10.00
Median $10.00
High $11.00
3 analysts
$10.00
$11.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 10, 2026 | Maxim Group | UPGRADE | Hold → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.48 ▲ +54.0% | $-0.64 — $-0.34 | 86% YoY | 3 |
| Next Q | $-0.43 ▲ +60.7% | $-0.58 — $-0.34 | 70% YoY | 3 |
| Current FY | $-2.05 ▲ +51.2% | $-2.85 — $-1.47 | 75% YoY | 3 |
| Next FY | $-1.60 ▲ +48.3% | $-2.56 — $-0.94 | 22% YoY | 3 |
Latest Reports
NEUTRAL
DEFA14A
4/10
Cellectar Biosciences filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting sched
Jun 5, 2026
BULLISH
Press
7/10
Cellectar Biosciences announced positive Phase 2 CLOVER WaM data at ASCO for iopofosine I 131 in post-BTKi Waldenström m
Jun 1, 2026
BEARISH
S-1/A
6/10
Cellectar Biosciences filed Amendment No. 1 to its S-1 registration statement to register up to 51,998,413 shares of com
May 29, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $262.9K | ADD |
| MORGAN STANLEY | $1.5K | NEAR_EXIT |
| BANK OF AMERICA CORP | $106.00 | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 7, 2026 | CARUSO JAMES | BUY | $25.0K |
| May 7, 2026 | CARUSO JAMES | BUY | $260.40 |
| May 7, 2026 | Longcor Jarrod | BUY | $25.0K |
| May 7, 2026 | Longcor Jarrod | BUY | $260.40 |
3 institutional holders with $264.5K total value (89,666 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 89,120 | $262.9K | 99.4% | ADD +36.7% |
| 2 | MORGAN STANLEY | 510 | $1.5K | 0.6% | NEAR_EXIT -91.4% |
| 3 | BANK OF AMERICA CORP /DE/ | 36 | $106.00 | 0.0% | ADD +33.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 65,171 | 89,120 | +36.7% | $262.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 27 | 36 | +33.3% | $106.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 24,900 | 0 | -100.0% | $0.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 24,900 | — | $139.4K | 2025-Q3 |
| UBS Group AG | TRIM | 3,620 | 908 | -74.9% | $5.1K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 2 | 27 | +1250.0% | $152.00 | 2025-Q3 |
| VANGUARD GROUP INC | NEW | — | 56,341 | — | $400.6K | 2025-Q2 |
| UBS Group AG | NEW | — | 3,620 | — | $25.7K | 2025-Q2 |
| UBS Group AG | EXIT | 920,352 | 0 | -100.0% | $0.00 | 2025-Q2 |
| VANGUARD GROUP INC | EXIT | 1,721,838 | 0 | -100.0% | $0.00 | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 83,099 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 376,199 | 920,352 | +144.6% | $289.9K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 43,600 | 419,358 | +861.8% | $132.2K | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 178,719 | 15,305 | -91.4% | $4.8K | 2025-Q1 |
| UBS Group AG | DOUBLED | 2,577 | 376,199 | +14498.3% | $112.5K | 2024-Q4 |
| MORGAN STANLEY | ADD | 139,231 | 178,719 | +28.4% | $53.4K | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 67,803 | 43,600 | -35.7% | $13.0K | 2024-Q4 |
| MORGAN STANLEY | ADD | 83,442 | 139,231 | +66.9% | $298.0K | 2024-Q3 |
2 unique insiders with 4 transactions. Net insider value: $50.5K ($50.5K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 7, 2026 | CARUSO JAMES V | Chief Executive Officer | BUY | 8,680 | $2.88 | $25.0K |
| May 7, 2026 | CARUSO JAMES V | Chief Executive Officer | BUY | 26,040 | $0.0100 | $260.40 |
| May 7, 2026 | Longcor Jarrod | Chief Operating Officer | BUY | 8,680 | $2.88 | $25.0K |
| May 7, 2026 | Longcor Jarrod | Chief Operating Officer | BUY | 26,040 | $0.0100 | $260.40 |
10 SEC filing reports analyzed. Sentiment: 1 bullish, 5 bearish, 1 mixed, 3 neutral. Avg impact: 5.4/10.
NEUTRAL
DEFA14A
4/10
Cellectar Biosciences filed additional definitive proxy soliciting materials (DEFA14A) for its 2026
Jun 5, 2026
BEARISH
S-1/A
6/10
Cellectar Biosciences filed Amendment No. 1 to its S-1 registration statement to register up to 51,9
May 29, 2026
BEARISH
S-1
6/10
Cellectar Biosciences filed an S-1 registration statement to register up to 51.2 million shares of c
May 19, 2026
MIXED
8-K
7/10
Cellectar Biosciences reported Q1 2026 net loss of $5.7M ($1.33/share), narrower than the $6.6M loss
May 14, 2026
BULLISH
PRESS-RELEASE
6/10
Cellectar Biosciences reported Q1 2026 EPS of -$1.33, beating the -$1.89 consensus, but remains pre-
May 14, 2026
BEARISH
CLUSTER
6/10
CLRB's CEO and COO purchased $50K in shares at $2.88, a premium to the heavily dilutive $34.95M offe
May 12, 2026
NEUTRAL
PRESS-RELEASE
2/10
Cellectar Biosciences announced it will report Q1 2026 financial results on May 14, 2026, with no ac
May 11, 2026
BEARISH
8-K
8/10
Cellectar Biosciences files securities purchase agreements for a massive $34.95M registered direct o
May 8, 2026
BEARISH
424B5
7/10
Cellectar Biosciences is conducting a dilutive public offering of 1.6M shares at $2.65 (6.4% discoun
May 6, 2026
NEUTRAL
10-K/A
2/10
Cellectar Biosciences filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information
Apr 30, 2026
BULLISH
7/10
Cellectar Biosciences announced positive Phase 2 CLOVER WaM data at ASCO for iopofosine I 131 in pos
Jun 1, 2026
BULLISH
8/10
Cellectar Biosciences announced updated 12-month follow-up data from its Phase 2b CLOVER WaM trial o
May 5, 2026
MIXED
6/10
Cellectar Biosciences announced the first patient enrollment in its Phase 1b trial of CLR 125 for tr
Apr 14, 2026
MIXED
6/10
Cellectar Biosciences reported its 2025 financial results, showing a significantly reduced net loss
Mar 4, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$10.33 mean target
+299.0% upside
Strong Buy (3.00)
$10.00 Low
$11.00 High
| Metric | Value |
|---|---|
| Current Price | $2.59 |
| Target Low | $10.00 |
| Target Mean | $10.33 |
| Target Median | $10.00 |
| Target High | $11.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.48 | $-0.64 | $-0.34 | 85.7% | +54.0% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.43 | $-0.58 | $-0.34 | 69.7% | +60.7% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-2.05 | $-2.85 | $-1.47 | 75.5% | +51.2% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-1.60 | $-2.56 | $-0.94 | 21.7% | +48.3% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.483 | |
| 7d ago | $-0.600 | +0.117 |
| 30d ago | $-1.050 | +0.567 |
| 60d ago | $-1.050 | +0.567 |
| 90d ago | $-1.987 | +1.503 |
1 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 10, 2026 | Maxim Group | UPGRADE | Hold | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 3 | 4 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| Feb 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| Jan 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 1, 2026
fda
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
<p align="center"><em>Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in </em><br><em>Subset Analysis of Patients T
May 14, 2026
earnings
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
<p align="center"><em>Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) </
May 11, 2026
earnings
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
<p align="left">FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceut
May 11, 2026
earnings_calendar
CLRB Q1 2026 Earnings Scheduled — 2026-05-11
May 6, 2026
short_interest
FTD: CLRB — 822,428 shares ($2.6M) failed to deliver
Settlement: 20260506, Price: $3.18, FTD Value: $2,615,321.04, CELLECTAR BIOSCIENCES INC COM
May 5, 2026
fda
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
<p align="center"><em>83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 months</em></p>
May 5, 2026
short_volume
Short Volume: CLRB — 57.9% short (6.3M / 10.8M)
Short: 6,275,692 | Exempt: 79,262 | TRF Vol: 10,846,597 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
fda
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to determine recommen
Apr 1, 2026
Clinical Trial
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: Iopofosine I 131 single dose (Phase 2)
Trial: Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Sponsor: Cellectar Biosciences, Inc.
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: Iopofosine I 131 single dose (Phase 2)
Trial: Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Sponsor: Cellectar Biosciences, Inc.
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: Iopofosine I 131 single dose (Phase 2)
Trial: Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Sponsor: Cellectar Biosciences, Inc.
Mar 11, 2026
earnings_calendar
CLRB Q4 2025 Earnings After Market Close — 2026-03-11
Mar 4, 2026
earnings
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
<p align="center"><em>On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potentia